JPRN-UMIN000004685招募中2 期
Phase II study of Combination Therapy of Pemetrexed/Carboplatin/Bevacizumab for Advanced Non-small-cell lung cancer - Phase II study of Combination Therapy of Pemetrexed/Carboplatin/Bevacizumab for Advanced Non-small-cell lung cancer
ational Hospital Organization Hokkaido Medical Center0 个研究点目标入组 38 人开始时间: 2010年12月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Uncontrolled complication unstable angina or myocardiac infarction within 3 months uncontrolled DM and hypertension uncontrolled infection active interstitial pneumonia active gastiric ulcer active concominant cancer illeus 2)patients who cannot been given Bevacizumab with great vessel invasion cavity in tumor current or previous histoty ofhemoptysis(2.5ml)due to NSCLC receiving anticoagulant drug(except Aspirin under 325mg/day) untreated current brain metastasis 3)history of sever allergy 4)severe SVC syndrome 5)uncontrolled malignant pleuritis 6)history of pregnancy or lactation 7)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
招募中
2 期
Phase II Study of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy for Elderly Advanced Non-squamous and Non-small Cell Lung Cancer.on-squamous non-small-cell lung cancerJPRN-UMIN000006139Tochigi Thoracic Oncology Research Organization50
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEstudio en fase II de pemetrexed en combinación con cisplatino y cetuximab en el carcinoma de células escamosas de cabeza y cuello recurrente o metastásicoRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCarcinoma de células escamosas de cabeza y cuello recurrente o metastásicoMedDRA version: 12.0Level: LLTClassification code 10063569Term: Metastatic squamous cell carcinomaEUCTR2009-011611-21-ESEli Lilly and Company Ltd.65
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-DEEli Lilly and Company Ltd.65
进行中（未招募）
1 期
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-GBEli Lilly and Company Ltd.65
进行中（未招募）
1 期
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckMedDRA version: 13.1Level: PTClassification code 10063569Term: Metastatic squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011611-21-BEEli Lilly and Company Ltd.65